Huang X, Yang Y, Zhu J, Gao X, Wang G, Tan H, Liang Y, Li J
Emergency Centre of Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Int Med Res. 2009 Nov-Dec;37(6):1928-36. doi: 10.1177/147323000903700631.
This cross-sectional, retrospective study was designed to evaluate the current clinical applications and acute hepatotoxicity of intravenous amiodarone administration at a hospital in China. Clinical data were collected from 1214 patients receiving intravenous amiodarone treatment between October 2003 and September 2005. Baseline patient characteristics, drug indications, administration records and acute hepatotoxicity associated with the drug were examined. Amiodarone was used primarily in arrhythmic patients with obvious cardiac dysfunction. Atrial fibrillation and ventricular arrhythmia were the two most commonly treated dysfunctions. Incorrect indications and administration methods were also noted. Hepatotoxicity occurred in 12.6% of the patients, but was mild in most cases. Males showed a higher incidence of hepatotoxicity than females. The use of amiodarone was considered to be reasonable and standardized, but there was still considerable room for improvement, particularly in the standardization of administration guidelines. Intravenous amiodarone can cause hepatotoxicity and hepatic function tests should be performed soon after giving amiodarone intravenously.
本横断面回顾性研究旨在评估中国一家医院静脉注射胺碘酮的当前临床应用情况及急性肝毒性。收集了2003年10月至2005年9月期间接受静脉注射胺碘酮治疗的1214例患者的临床资料。检查了患者的基线特征、用药指征、给药记录以及与该药物相关的急性肝毒性。胺碘酮主要用于有明显心脏功能障碍的心律失常患者。心房颤动和室性心律失常是最常治疗的两种功能障碍。还注意到用药指征和给药方法不正确的情况。12.6%的患者出现肝毒性，但大多数病例症状较轻。男性肝毒性发生率高于女性。胺碘酮的使用被认为是合理和规范的，但仍有很大的改进空间，尤其是在给药指南的标准化方面。静脉注射胺碘酮可导致肝毒性，静脉注射胺碘酮后应尽快进行肝功能检查。
